

TBI - Neurocritical care and medical management




김태정
서울의대

Kim Tae Jung
Department of Neurology, Seoul National University Hospital

Contents

- Introduction
- Managements of TBI
 - IICP control
 - Medical managements in NICU
- Conclusion

Epidemiology of TBI



Epidemiology of TBI

- Trauma is the leading cause of death in young ages
- Traumatic brain injury (TBI)
 - 1.6 million TBIs each year
 - over 50,000 deaths per year in the United States
 - overall mortality rates of 20–30% and associated with disability
 - The economic impact is over \$80 billion in the US alone.
 - in high-income countries: the number of elderly people with TBI is increasing, mainly due to falls
 - low-middle income countries: the burden of TBI from road traffic incidents is increasing.

TBI in Korea





- A Multicenter Analysis Using Korean Neuro-Trauma Data Bank System 2010–2014 (KNTDB Investigators)

Table 2. Incidence of traumatic brain injury according to age distribution and sex. J Korean Neurosurg Soc 62 (2): 243-255, 2019.

Age	Men		Women		Incidence (%)
	DS-KNSO	PI%	DS-KNSO	PI%	
05-09	958491	167	925432	84	0.008
10-14	795151	356	1000590	91	0.009
15-19	150844	533	780920	98	0.012
20-24	227366	64	488911	54	0.021
25-29	128569	20	370968	43	0.011
Total	2605721	540	3658876	364	0.011

PI%: patients in the study (n=406), DS-KNSO: Demographic statistics of the Korea National Statistical Office in March 2014


Characteristics	Non-survivors (n=140)	Survivors (n=494)	Total patients (n=406)	Mortality (%)	p-value
Case#					0.001
Fall	15 (25.0)	383 (45.3)	398	3.77	
Traffic accidents	29 (45.0)	230 (28.8)	259	11.65	
Assault	2 (3.0)	13 (1.5)	15	13.33	
Others	3 (4.5)	39 (4.5)	42	5.17	
Unknown	7 (10.5)	80 (9.5)	87	8.05	
Unavailable	2 (3.0)	95 (11.2)	97	2.06	
Diagnoses					0.029
A-EDH	4 (6.0)	35 (4.5)	39	6.78	
A-SDH	37 (55.5)	415 (49.1)	452	8.19	
T-SAH	4 (6.0)	120 (15.2)	124	6.52	
Contusd-KCH	3 (4.5)	12 (1.5)	15	3.75	
DAI	0	3 (0.4)	3	0	
Others	3 (4.5)	162 (19.1)	165	5.82	



Decompressive Craniectomy

- Decompressive craniectomy: relieving elevated intracranial pressure with outcome improvement in severe TBI with aggravating neurological symptom
- Bifrontal decompressive craniectomy to control ICP
 - In Severe TBI patients with ICP > 20 mmHg
 - Bifrontal decompressive craniectomy (DC) is better than standard ICU management for good outcome?

Severe TBI with herniation



Bifrontal decompressive craniectomy

RESCUEicp Trial: RCT of DC (unilateral or bilateral) vs. standard care in TBI patients with refractory elevated intracranial pressure (>25 mm Hg).




Figure 1. Stages of Therapeutic Management. Decompressive craniectomy in patients with refractory intracranial hypertension after TBI resulted in lower mortality, higher rates of vegetative state, and lower severe disability. But, rates of moderate disability and good recovery were similar in two groups.

Bifrontal decompressive craniectomy

- Bifrontal DC is not recommended to improve outcomes in severe TBI patients with diffuse injury (without mass lesions), and with ICP elevation (ICP > 20mmHg).
- The treatment of DC target goal ICP ≤ 20 mm Hg is wrong goal.

- Monitoring for IICP control
 - Cerebral perfusion pressure (CPP): pressure gradient across the cerebral vascular bed, between blood inflow and outflow (CPP = MAP- ICP)
 - Cerebral autoregulation: maintenance of cerebral blood flow (CBF) over a wide range of CPPs : Pressure reactivity index (PRx) and RAP index
 - Brain tissue oxygenation


Table 1. Variables assessed in multicenter monitoring

Parameter	Monitor	Target	Comment	EDA
Intracranial pressure	Extracranial drain Cannula (sterile) monitor ICP catheter	Continuous ICP monitoring, CP goal pressure	Calculate CP and ICP	Assessed
Brain oxygenation	Jugular bulb oximetry Near infrared spectroscopy	Central brain tissue hypoxia Detect global oxygen consumption To saturation not oxygen tension	Non-invasive, frontal area I _{ox} saturation Invasive, information on focal sites	Assessed Assessed
Cerebral blood flow	Biacoustic Doppler monitor	Frontal tissue CBF		Assessed
EEG	Continuous EEG	EEG slowing and seizure activity	Seizure and postictal information, qEEG (CSA) may help detect quantitative information	Assessed
Metabolites	Noninvasive apparatus: near-infrared spectroscopy	Brain tissue deoxygenation	High ICP, low glucose is defined as a metabolic crisis	Under review

Journal of Stroke 2011;15(12):99-108.

Targeted temperature management (Hypothermia)


- Mechanism of TTM for treatment
- Reduction in cerebral metabolism (CMRO2) by approximately 6% per 1°C. Less oxygen and glucose consumption
- Promotion of cerebral vasoconstriction: Decreased ICP and brain edema
- Protection of neuro-vascular injury: Decreased ischemic cascade, especially inflammation response, decreased vascular permeability



Neuropharmacology, 2018 May 15;15A(Ph):302-309.


Targeted temperature management (Hypothermia)

- Very early hypothermia induction in patients with severe brain injury (the National Acute Brain Injury Study: Hypothermia II): a randomised trial. Lancet Neurol 2011; 10: 131-39
- RCT of hypothermia (33°C) vs. normothermia within 2.5 hours after severe TBI and Maintained for 48 h



This study did not show the utility of hypothermia as a primary neuroprotective strategy in patients with severe traumatic brain injury.

Targeted temperature management in TBI



- Early, short-term, and prophylactic hypothermia is not recommended to improve outcomes in patients with diffuse injury.
- However, traumatic brain injury patients with elevated intracranial hypertension could benefit from hypothermia in therapeutic management instead of prophylaxis when initiated within 24 h.

Hyperosmolar therapy

- Osmotic agents: control brain edema and IICP
- Pulls free water across the semipermeable membrane of the blood-brain barrier (BBB).
- Osmotic agent: mostly stays in serum and raises serum osmolality compared to the osmolality in brain.
- Mannitol (peripheral line and central line)
 - Osmotic diuretics: sugar or sugar alcohol
 - Duration: 6-8 hours
 - Action time: 15 min after injection
 - Osmotic diuresis and AKI
- Hypertonic saline (central line)
 - Generally comes in 3%, 7%, and 23.4%
 - Number of osmoles similar: 1,000 mL 0.9% = 250 mL 3% = 30 mL 23.4%
 - May be given as a bolus (23.4% or 11.7% in Korea)
 - Not an osmotic diuretic (mannitol)

Mannitol & Hypertonic saline

Sodium Chloride Concentration (%)	Osmolarity (mOsm/L)	Sodium Concentration (mEq/L)
0.9	308	154
1.7	582	291
3.0	1026	513
7.5	2566	1283
10.0	3424	1712
23.4	8008	4004


For comparison, the osmolarity of 20% mannitol is 1098 mOsm/L.



- Mannitol dose: 0.5g/Kg – 1.5g/Kg (1g/Kg)
 - <0.5g/Kg dose: less effect of controlling ICP (20%)
- In Korea : 11.7% NaCl: 40mEq/20cc - 60cc IV shooting [NACL4IP]

Forsyth LL, et al. Pharmacotherapy. 2008 Apr;28:469-84

Monitoring and Complications



- Monitoring Osmolar gap (OG) during mannitolization: estimating mannitol concentration
 - Actual serum osmolality – Calculated serum osmolality (<55 mOsm)
 - Calculated serum osmolality: 2Na + BUN/2.8 + glucose/18
 - Not stopping based on serum osmolality

Table 3. Avoiding Adverse Effects of Osmotic Agents

Complication	Mannitol	Hypertonic Saline
Renal Failure	Avoid continuous infusion, repeat high dosing	Avoid prolonged hypernatremia >160 mEq/L
Rhabdomyolysis	Allow clearance prior to repeat dose	Allow clearance prior to repeat dose
Metabolic Acidosis	na	Reduce chloride in admixture
Hypokalemia	Concurrent volume resuscitation	Add potassium to fluids
Hypotension	Concurrent volume resuscitation	na


Garcia-Morales EJ, et al. Crit Care Med. 2004;32(4):886-891
Hosain ME, et al. J Intensive Care Med. 2013;28(1):3-11

Steroid in TBI

Final results of MRC CRASH, a randomised placebo-controlled trial of intravenous corticosteroid in adults with head injury—outcomes at 6 months

Lancet 2005; 365: 1957-59


- Randomly allocated 10 008 adults with head injury and a Glasgow Coma Scale score of 14 or less within 8 h of injury
- 48-h infusion of corticosteroid (methylprednisolone, 2g loading over 1 and 0.4g maintenance dose/h) vs. placebo.




Steroids increased mortality and poor outcome after TBI.

Steroid in TBI

Analysis 1.3. Comparison 1 Any steroid administered in any dose against no steroid, Outcome 1 Death at end of follow-up (AOR)



Analysis 1.4. Comparison 1 Any steroid administered in any dose against no steroid, Outcome 4 Major or significant gastrointestinal bleed



- The use of steroids is not recommended for improving outcome or reducing ICP.
- In severe TBI patients high dose methylprednisolone was associated with increased mortality and is contraindicated.

Cochrane Database Syst Rev. 2005 Jun 25;(1):CD001016

Sedation and Analgesic

- Analgesics, and sedatives: prophylaxis or control of elevated ICP
- Proper sedation
 - Light and reversible sedation is recommended to allow repeated neurological evaluation.
 - Minimizing hypotension and decreased cardiac output which may lead to hypoxia and low CPP
- Sedative drugs
 - Dexmedetomidine: Selective α_2 receptor agonist (light sedation and pain control), Potentially significant hypotension and bradycardia or hypertension, 0.3 – 1.5 mcg/kg/h
 - Remifentanyl: ultra-short acting opioid, prompt reversal of analgesia and sedation, chest wall rigidity with higher dose, 0.03-0.25 mcg/kg/min
 - Midazolam and propofol: deep sedation, side effect and context sensitive half-life
 - High-dose barbiturate is recommended to control refractory elevated ICP condition.

	Propofol	Midazolam	Lorazepam	Fentanyl	Dexmedetomidine
Rapid onset	+++	+++	+	+++	+++
Fast recovery	+++	++	+	++	+++
Easily titrated	+++	++	+	++	+++
ICP reduction					
CBP reduction					
CMRO ₂ reduction					
MAP					

Textbook of Neurointensive Care.

Target blood pressure in TBI

- Maintaining SBP at ≥ 100 mm Hg for patients 50 to 69 years old or at ≥ 110 mm Hg or above for patients 15 to 49 or over 70 years old may be considered to decrease mortality and improve outcomes.
- Target MAP ≥ 65 mmHg

Optimal SBP and mortality in patients moderate to severe TBI patients.


Age group	Optimal SBP	Mortality	AOR	95% CI	p-Value
15-49 years (n = 10284)	<110mm Hg	21%	1.98	1.65-2.39	<0.0001
50-69 years (n = 3093)	<100mm Hg	29%	2.20	1.46-3.31	0.0002
50-69 years (n = 3093)	≥ 110 mm Hg	20%	1.60	1.13-2.28	0.009
≥ 70 years (n = 2356)	<110mm Hg	38%	1.92	1.35-2.74	0.0003

Adjusted odds ratios (AOR): Optimal SBP is compared to SBP reference groups, adjusting for age, gender, ISS ≥ 16 , and GCS ≤ 8 ; reference groups for age 15-49 (≥ 110 mmHg) for age 50-69 (≥ 100 mmHg), for age ≥ 70 (≥ 110 mmHg)

Injury. 2012 Nov;43(11):1893-7.

Cerebral perfusion pressure (CPP) in TBI

- CPP is the blood pressure metric to which brain autoregulatory mechanisms respond.



- Target CPP value for survival and favorable outcomes: 60 and 70 mm Hg (at least above 50 mmHg).
- Avoiding aggressive attempts to maintain CPP above 70 mm Hg with fluids and pressors related to respiratory failure in older patients.

CPP (Cerebral perfusion pressure) = MAP (mean arterial pressure) – ICP (intracranial pressure)

J Neurol Neurosurg Psychiatry 2002;73(Suppl 1):i23-i27

Medical managements in TBI

Arterial partial pressure of oxygen (PaO2)

- Arterial partial pressure of oxygen (PaO2) level between 60 and 100 mmHg during interventions for life-threatening hemorrhage or emergency neurosurgery.
- SpO2 < 90% (corresponding near to a PaO2 of 60 mmHg) and hyperoxia (defined as a PaO2 > 200 mmHg) are associated with poor outcomes in TBI.
- Avoid hypoxia (PaO2 < 60 mmHg) and hyperoxia (PaO2 > 200 mmHg)

Table 3. Effect of Hypoxia Compared With Normoxia on Outcome Measures*

	OR (95% CI)	P Value
<100 vs 100-200 mm Hg		
Mortality	2.20 (1.33-3.63)	.002 ^b
Discharge GCS score 3-8	1.66 (1.01-2.73)	.043 ^b
HLOS	0.38 (0.25-0.58)	<.001 ^a
ICULOS	0.40 (0.25-0.66)	<.001 ^a

Table 4. Effect of Hyperoxia Compared With Normoxia on Outcome Measures*

	OR (95% CI)	P Value
>200 vs 100-200 mm Hg		
Mortality	1.55 (1.15-1.97)	.002 ^b
Discharge GCS score 3-8	1.52 (1.18-1.96)	.001 ^b
HLOS	0.75 (0.60-0.94)	.01 ^a
ICULOS	0.92 (0.74-1.15)	.46

Arch Surg. 2012;147(11):1042-1046.

Nutrition

- Feeding patients to attain basal caloric replacement at least by the fifth day and at most by the seventh day post-injury is recommended to decrease mortality.
- EN supports the functional integrity of the gut
 - Food in gut: activated pathogenic microorganism in the gut and maintaining tight junctions between the intraepithelial cells stimulating blood flow




Figure 4. Early enteral nutrition (EN) vs delayed EN, mortality. Figure 5. Enteral nutrition (EN) vs parenteral nutrition (PN), infection complications. 2016 SCCM & ASPEN guidelines

Transfusion

- There are no current recommendations regarding appropriate hemoglobin or hematocrit concentrations in patients with severe TBI.
- The Transfusion Requirements in Critical Care (TRICC) study
 - trigger for transfusion Hb > 10 g/dl group and the trigger for transfusion Hb > 7 g/dl group
 - Mortality at 30 days and 60 days

Table 2. Outcomes*

Outcome Measure	Restrictive Strategy (Hb < 7 g/dL)	Liberal Strategy (Hb < 10 g/dL)	Absolute Difference Between Groups	95% CI	P Value
Death — no. (%)	79 (28.7)	86 (32.3)	4.7	-0.8 to 10.2	0.11
ICU stay	90 (22.7)	111 (34.3)	3.7	-2.1 to 9.5	0.21
HLOS	90 (22.7)	96 (30.2)	2.3	-2.8 to 7.6	0.39
ICULOS	90 (22.7)	110 (34.3)	2.2	-3.4 to 7.9	0.20

- There is no benefit of a liberal transfusion strategy (goal, 10 g/dL) compared to a restrictive strategy (goal, 7 g/dL) could be demonstrated.

- Hb threshold of 7 g/dl is recommended value of Hb in TBI polytrauma patients.

N Engl J Med. 1999 Feb 11;340(6):409-17.

Prophylaxis

- Infection
 - Prophylactic antibiotics is not recommended for preventing infection.
 - Antimicrobial-impregnated catheters may be considered to prevent catheter-related infections during EVD.
 - Early tracheostomy (<10 days) is recommended to reduce mechanical ventilation in severe TBI.
- Deep vein thrombosis (DVT)
 - 54% incidence of deep venous thrombosis without prophylactic treatment and a 25% incidence in patients with isolated TBI treated with sequential compression devices.
 - Low molecular weight heparin (LMWH) or low-dose unfractionated heparin may be used in combination with mechanical prophylaxis (after 48-72 h).
 - Consider stocking and ICP in patients with increased risk for expansion of intracranial hemorrhage.

Guidelines for the Management of Severe Traumatic Brain Injury 4th Edition.

Prophylaxis

- Seizure
 - clinical post traumatic seizure (PTS): ~ 12%,
 - subclinical seizures: 20% to 25% in EEG
 - early PTS occur within 7 days of injury and late PTS occur after 7 days following injury
 - Early PTS have not been associated with worse outcomes
 - Early PTS: AED for a few weeks/ late PTS: AED for several years
- Prophylactic use of AED
 - Prophylactic use of phenytoin or valproate is not recommended for preventing late PTS.
 - There is insufficient evidence to recommend levetiracetam compared with phenytoin regarding efficacy in preventing early post-traumatic seizures and toxicity.

Guidelines for the Management of Severe Traumatic Brain Injury 4th Edition

Neuropharmacologic therapies for recovery

- Amantadine: act as an N-methyl-D-aspartate antagonist and indirect dopamine agonist.
- Amantadine for TBI: Diffuse axonal injury after TBI → Damage and death of neurons → Associated with a reduction in dopamine release → amantadine increase dopamine
- RCT of amantadine therapy (100 mg bid for 14 days - 150 mg vid for 7 days – 200mg bid for 7 days vs. placebo for 4 weeks in a vegetative or minimally conscious state 4 to 16 weeks after traumatic brain injury

N Engl J Med 2012;366:819-26.




Figure 1. Mean Disability Rating Scale (DRS) Scores during the 4-Week Assessment Period, According to Study Group.




Figure 2. Post Hoc Analysis of the Distribution of DRS Scores by Outcome Category.

Neuropharmacologic therapies for recovery

The effects of amantadine on traumatic brain injury outcome: a double-blind, randomized, controlled, clinical trial

BRAIN INJURY 2018, VOL. 32, NO. 8, 1050-1055.

- TBI patients who scored nine or lower on the Glasgow Coma Scale (GCS)
- The protocol included administration of the drug (placebo or amantadine) for 6 week → **no beneficial effect on outcome**

Table 3. The results of this study.

	Amantadine (N = 105)	Placebo (N = 111)	P-value
Male sex	18(100%)	18(85.7%)	0.09
Age group (yrs)	32.16 ± 13.87	40.95 ± 20.86	0.13
Age group number	14(71.7%)	11(52.4%)	-
16-35 yrs	4(21%)	5(23.8%)	
36-55 yrs	11(57%)	6(28.2%)	
56-75 yrs	0	0	
76-95 yrs	0	0	
Trauma mechanism	4(21.4%)	3(13.5%)	
Motor vehicle accident	4(21%)	5(23.8%)	
Fallings	5(26.2%)	3(13.5%)	
Direct trauma	1(5.2%)	1(4.5%)	
Subzero	1(5.2%)	1(4.5%)	
Mechanical ventilation at the start of study	1(5.2%)	2(9.0%)	0.11
Mean GCS			
Beginning day	7.1 ± 1.56	6.95 ± 1.74	0.77
Third day	8.18 ± 2.65	7.78 ± 2.65	0.35
Seventh day	11.18 ± 3.28	9.33 ± 3.29	0.1
Mean GCS Motor			
Beginning day	4.36 ± 1.01	4.28 ± 1.27	0.82
Third day	4.77 ± 0.94	4.39 ± 1.42	0.31
Seventh day	5.22 ± 1.93	4.77 ± 1.35	0.27
Mean GCS Eye			
Beginning day	1.52 ± 0.61	1.52 ± 0.61	0.99
Third day	2.00 ± 0.76	1.84 ± 0.76	0.53
Seventh day	2.88 ± 0.96	2.44 ± 0.78	0.13
Mean GCS Verbal			
Beginning day	1.21 ± 0.41	1.14 ± 0.25	0.58
Third day	1.94 ± 1.21	1.52 ± 1.07	0.28
Seventh day	3.11 ± 1.52	2.13 ± 1.52	0.38
Mean FOUR score			
Beginning day	8.81 ± 2.23	7.52 ± 2.81	0.46
Third day	9.79 ± 2.81	8.26 ± 3.41	0.15
Seventh day	12.32 ± 3.32	10.11 ± 4.01	0.07
SECT/F-FOUR	4	2	0.84
FOUR score 7-FOUR score	4.17	2.67	0.88
Mortality			
In Hospital	4	0	0.9
From discharge to 6 months follow-up	2	0	
Mean time from trauma to start study (days)	24.96 ± 16.33	21.13 ± 13.97	0.49
Mean time from trauma to start study (days)	3.21 ± 2.32	3.42 ± 2.67	0.78
After 6 months			
MRS	23.1 ± 4.22	20.3 ± 5.2	0.2
ODS	4.09 ± 0.99	4.5 ± 0.7	0.29
ODS	4.42 ± 0.86	3.8 ± 1.33	0.34
APACHE	66.45 ± 26.57	81 ± 17.91	0.25
Number of drug usage	2	6	0.11
Infection Factors			

Conclusions

- Not recommended prophylactic DC and hypothermia after TBI
- DC and hypothermia for IICP control
- Optimal hyperosmolar therapy with monitoring
- Proper sedation for controlling ICP and pain
- Maintaining MAP and CPP for cerebral autoregulation
- Optimal transfusion (Hb < 7g/dl)
- Not recommended prophylactic AED and antibiotics